Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK

被引：9

作者：

Damm-Welk, Christine ^{[1
,2
]}

Siddiqi, Faraz ^{[3
]}

Fischer, Matthias ^{[4
,5
,6
]}

Hero, Barbara ^{[4
]}

Narayanan, Vignesh ^{[7
]}

Camidge, David Ross ^{[7
]}

Harris, Michael ^{[3
]}

Burke, Amos ^{[8
]}

Lehrnbecher, Thomas ^{[9
]}

Pulford, Karen ^{[10
]}

Oschlies, Ilske ^{[11
]}

Siebert, Reiner ^{[12
,13
]}

Turner, Suzanne ^{[3
]}

Woessmann, Wilhelm ^{[1
,2
]}

机构：

[1] Univ Giessen, NHL BFM Study Ctr, Giessen, Germany

[2] Univ Giessen, Dept Paediat Haematol & Oncol, Feulgenstr 12, D-35392 Giessen, Germany

[3] Univ Cambridge, Dept Pathol, Cambridge, England

[4] Univ Cologne, Dept Paediat Haematol & Oncol, Cologne, Germany

[5] Univ Cologne, Fac Med, Ctr Mol Med Cologne, Cologne, Germany

[6] Max Planck Inst Metab Res, Cologne, Germany

[7] Univ Colorado, Ctr Canc, Aurora, CO USA

[8] Addenbrookes Hosp, Dept Paediat Oncol, Cambridge, England

[9] Goethe Univ Frankfurt, Dept Paediat Haematol & Oncol, Frankfurt, Germany

[10] Univ Oxford, Nuffield Div Clin Lab Sci, Oxford, England

[11] Univ Kiel, Dept Pathol, Kiel, Germany

[12] Univ Kiel, Inst Human Genet, Campus Kiel, Kiel, Germany

[13] Univ Hosp Schleswig Holstein, Campus Kiel, Kiel, Germany

来源：

JOURNAL OF CANCER | 2016年 / 7卷 / 11期

基金：

英国惠康基金;

关键词：

ALK-antibody titre; NSCLC; neuroblastoma; lymphoma; ANAPLASTIC LYMPHOMA KINASE; LARGE-CELL LYMPHOMA; LUNG-CANCER; TYROSINE KINASE; NEUROBLASTOMA; GENE; FEATURES; DISEASE; ALCL; IDENTIFICATION;

D O I：

10.7150/jca.15238

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Patients with Nucleophosmin (NPM)- Anaplastic Lymphoma Kinase (ALK) fusion positive Anaplastic Large Cell Lymphoma produce autoantibodies against ALK indicative of an immune response against epitopes of the chimeric fusion protein. We asked whether ALK-expression in other malignancies induces specific antibodies. Antibodies against ALK were detected in sera of one of 50 analysed ALK-expressing neuroblastoma patients, 13 of 21 ALK positive non-small cell lung carcinoma (NSCLC) patients, 13 of 22 ALK translocation-positive, but NPM-ALK-negative lymphoma patients and one of one ALK-positive rhabdomyosarcoma patient, but not in 20 healthy adults. These data suggest that boosting a pre-existent anti-ALK immune response may be more feasible for patients with ALK-positive NSCLC, lymphomas and rhabdomyosarcomas than for tumours expressing wild-type ALK.

引用

页码：1383 / 1387

页数：5

共 50 条

[31] ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions
Van Roosbroeck, Katrien
Cools, Jan
Dierickx, Daan
Thomas, Jose
Vandenberghe, Peter
Stul, Michel
Delabie, Jan
De Wolf-Peeters, Chris
Marynen, Peter
Wlodarska, Iwona
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (03): : 509 - 513
[32] Activation of IGF-1R pathway and NPM-ALK G1269A mutation confer resistance to crizotinib in NPM-ALK positive lymphoma
Li, Yanrong
Wang, Kai
Zhang, Jingdong
CANCER RESEARCH, 2018, 78 (13)
[33] NPM-ALK-reactive T-cell responses in children and adolescents with NPM-ALK positive anaplastic large cell lymphoma
Singh, Vijay Kumar
Werner, Sebastian
Schwalm, Simone
Lennerz, Volker
Ruf, Stephanie
Stadler, Serena
Hackstein, Holger
Reiter, Alfred
Woelfel, Thomas
Damm-Welk, Christine
Woessmann, Wilhelm
ONCOIMMUNOLOGY, 2019, 8 (09):
[34] NIPA (Nuclear Interaction Partner of ALK) Is Crucial for Effective NPM-ALK Mediated Lymphomagenesis
Kreutmair, Stefanie
Lippert, Lena Johanna
Klingeberg, Cathrin
Albers-Leischner, Corinna
Yacob, Salome
Shlyakhto, Valeria
Mueller, Tony
Mueller-Rudorf, Alina
Yu, Chuanjiang
Gorantla, Sivahari Prasad
Miething, Cornelius
Duyster, Justus
Illert, Anna Lena
FRONTIERS IN ONCOLOGY, 2022, 12
[35] Activation of IGF-1R pathway and NPM-ALK G1269A mutation confer resistance to crizotinib treatment in NPM-ALK positive lymphoma
Li, Yanrong
Wang, Kai
Song, Na
Hou, Kezuo
Che, Xiaofang
Zhou, Yang
Liu, Yunpeng
Zhang, Jingdong
INVESTIGATIONAL NEW DRUGS, 2020, 38 (03) : 599 - 609
[36] Combination ALK and MEK Inhibition in ALK-Positive Lung Cancer
Ashton, J.
Shrestha, N.
Bland, A.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S857 - S857
[37] Expanding the portfolio of anti-ALK weapons
Mologni, Luca
TRANSLATIONAL LUNG CANCER RESEARCH, 2015, 4 (01) : 5 - 7
[38] Activation of IGF-1R pathway and NPM-ALK G1269A mutation confer resistance to crizotinib treatment in NPM-ALK positive lymphoma
Yanrong Li
Kai Wang
Na Song
Kezuo Hou
Xiaofang Che
Yang Zhou
Yunpeng Liu
Jingdong Zhang
Investigational New Drugs, 2020, 38 : 599 - 609
[39] Interpretation of Anti-ALK Immunohistochemistry Results
Takeuchi, Kengo
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (07) : E67 - E68
[40] Detection of the NPM-ALK genomic rearrangement of Ki-1 lymphoma and isolation of the involved NPM and ALK introns
Ladanyi, M
Cavalchire, G
DIAGNOSTIC MOLECULAR PATHOLOGY, 1996, 5 (03) : 154 - 158

← 1 2 3 4 5 →